Unilateral Anterior Scleritis Following the Booster Shot of Inactivated COVID-19 (Sinopharm) Vaccine in a 52-Year-Old Woman: A Case Report.

Case Reports in Rheumatology Pub Date : 2024-12-28 eCollection Date: 2024-01-01 DOI:10.1155/crrh/6614757
Kimia Jazi, Mahnaz Rahimi, Fatemeh Hasani, Maryam Shirmohammadi, Maryam Masoumi
{"title":"Unilateral Anterior Scleritis Following the Booster Shot of Inactivated COVID-19 (Sinopharm) Vaccine in a 52-Year-Old Woman: A Case Report.","authors":"Kimia Jazi, Mahnaz Rahimi, Fatemeh Hasani, Maryam Shirmohammadi, Maryam Masoumi","doi":"10.1155/crrh/6614757","DOIUrl":null,"url":null,"abstract":"<p><p>The only way to mitigate the spread of coronavirus disease 2019 (COVID-19) pandemic was vaccines. While effective in decreasing the rate and severity of the disease, there also have been considerable adverse events. Since the birth of vaccines, adverse reactions accompanied the immunity, and COVID-19 vaccines are no exceptions. This is a report about a 52-year-old female patient who presented with bilateral redness of the eyes, with normal bilateral visual acuity, postbooster dose of the Sinopharm COVID-19 vaccine. She had no significant past history of any disease or any similar reactions after previous doses. All her physical examinations were normal. Ophthalmic examination disclosed diffuse erythema, and mild scleral edema consistent with bilateral anterior diffused scleritis with negative phenylephrine test. Thereafter, with a course of tapering doses of prednisolone (30 mg at the onset) combined with azathioprine (100 mg/day), over a 2-week period, the condition completely resolved. Very few vaccination-related adverse events may manifest an unrecognized underlying autoimmune vasculopathy which may also require urgent management. As in this case, ocular adverse events, as highlighted, are highly associated with undiagnosed autoimmune diseases and therefore warrant careful assessment by clinicians.</p>","PeriodicalId":9622,"journal":{"name":"Case Reports in Rheumatology","volume":"2024 ","pages":"6614757"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699981/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/crrh/6614757","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The only way to mitigate the spread of coronavirus disease 2019 (COVID-19) pandemic was vaccines. While effective in decreasing the rate and severity of the disease, there also have been considerable adverse events. Since the birth of vaccines, adverse reactions accompanied the immunity, and COVID-19 vaccines are no exceptions. This is a report about a 52-year-old female patient who presented with bilateral redness of the eyes, with normal bilateral visual acuity, postbooster dose of the Sinopharm COVID-19 vaccine. She had no significant past history of any disease or any similar reactions after previous doses. All her physical examinations were normal. Ophthalmic examination disclosed diffuse erythema, and mild scleral edema consistent with bilateral anterior diffused scleritis with negative phenylephrine test. Thereafter, with a course of tapering doses of prednisolone (30 mg at the onset) combined with azathioprine (100 mg/day), over a 2-week period, the condition completely resolved. Very few vaccination-related adverse events may manifest an unrecognized underlying autoimmune vasculopathy which may also require urgent management. As in this case, ocular adverse events, as highlighted, are highly associated with undiagnosed autoimmune diseases and therefore warrant careful assessment by clinicians.

52岁女性新冠肺炎(国药)灭活疫苗加强注射后单侧前巩膜炎1例
缓解2019冠状病毒病(COVID-19)大流行传播的唯一途径是疫苗。虽然有效地降低了发病率和疾病的严重程度,但也发生了相当多的不良事件。自疫苗诞生以来,不良反应一直伴随着免疫,COVID-19疫苗也不例外。这是一个关于52岁女性患者的报告,她表现为双侧眼睛发红,双侧视力正常,中国医药集团新冠肺炎疫苗加强剂量后。患者既往无明显疾病史,用药后无类似反应。她所有的身体检查都很正常。眼科检查发现弥漫性红斑和轻度巩膜水肿,符合双侧前弥漫性巩膜炎,苯肾上腺素试验阴性。此后,在2周的时间内,逐渐减少泼尼松龙(起病时30毫克)和硫唑嘌呤(100毫克/天)的剂量,病情完全缓解。极少数疫苗相关不良事件可能表现为未被识别的潜在自身免疫性血管病变,这也可能需要紧急处理。正如本病例所强调的,眼部不良事件与未确诊的自身免疫性疾病高度相关,因此需要临床医生仔细评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
35
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信